CA3200692A1 - Crystalline compounds - Google Patents

Crystalline compounds

Info

Publication number
CA3200692A1
CA3200692A1 CA3200692A CA3200692A CA3200692A1 CA 3200692 A1 CA3200692 A1 CA 3200692A1 CA 3200692 A CA3200692 A CA 3200692A CA 3200692 A CA3200692 A CA 3200692A CA 3200692 A1 CA3200692 A1 CA 3200692A1
Authority
CA
Canada
Prior art keywords
crystalline form
xrpd
radiation
exhibits
formulae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3200692A
Other languages
English (en)
French (fr)
Inventor
Franklin Bymaster
Walter Piskorski
Fred J. Fleitz
Yonglai Yang
David A. Engers
Valeriya Smolenskaya
Anthony Alexander Mckinney
Venkat Kusukuntla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka America Pharmaceutical Inc
Original Assignee
Otsuka America Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka America Pharmaceutical Inc filed Critical Otsuka America Pharmaceutical Inc
Publication of CA3200692A1 publication Critical patent/CA3200692A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
CA3200692A 2015-06-17 2016-06-17 Crystalline compounds Pending CA3200692A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181174P 2015-06-17 2015-06-17
US62/181,174 2015-06-17
CA2989431A CA2989431C (en) 2015-06-17 2016-06-17 Crystalline compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2989431A Division CA2989431C (en) 2015-06-17 2016-06-17 Crystalline compounds

Publications (1)

Publication Number Publication Date
CA3200692A1 true CA3200692A1 (en) 2016-12-22

Family

ID=57546597

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3200692A Pending CA3200692A1 (en) 2015-06-17 2016-06-17 Crystalline compounds
CA2989431A Active CA2989431C (en) 2015-06-17 2016-06-17 Crystalline compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2989431A Active CA2989431C (en) 2015-06-17 2016-06-17 Crystalline compounds

Country Status (25)

Country Link
US (6) US9708261B2 (enExample)
EP (3) EP4049997A1 (enExample)
JP (5) JP6896651B2 (enExample)
KR (1) KR102593783B1 (enExample)
CN (3) CN117466800A (enExample)
AU (2) AU2016279075C1 (enExample)
CA (2) CA3200692A1 (enExample)
CY (1) CY1125352T1 (enExample)
DK (1) DK3597189T3 (enExample)
ES (1) ES2922158T3 (enExample)
HK (1) HK1247125A1 (enExample)
HR (1) HRP20220829T1 (enExample)
HU (1) HUE059348T2 (enExample)
LT (1) LT3597189T (enExample)
MX (2) MX387591B (enExample)
MY (1) MY194868A (enExample)
NZ (2) NZ739044A (enExample)
PH (1) PH12017502324A1 (enExample)
PL (1) PL3597189T3 (enExample)
PT (1) PT3597189T (enExample)
SA (1) SA517390552B1 (enExample)
SG (1) SG10201911417PA (enExample)
SI (1) SI3597189T1 (enExample)
TW (1) TWI751998B (enExample)
WO (1) WO2016205762A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200801825B (en) 2005-07-27 2009-12-30 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
EP3080080A4 (en) * 2013-12-09 2017-08-16 Neurovance, Inc. Novel compositions
ES2922158T3 (es) 2015-06-17 2022-09-09 Otsuka America Pharmaceutical Inc Compuestos cristalinos
US11149004B2 (en) 2017-12-11 2021-10-19 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline form of EB-1020, processes for preparation and use thereof
CN114555557A (zh) * 2019-10-16 2022-05-27 大塚制药株式会社 森塔纳法啶的制备方法
US12698260B2 (en) * 2021-05-31 2026-08-04 Assia Chemical Industries Ltd. Solid state form of centanafadine HCL and process for preparation thereof
US12502358B1 (en) 2024-08-13 2025-12-23 Innovate Therapeutics Llc Centanafadine multiphasic controlled-release pharmaceutical formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005117630A (ru) 2002-11-08 2006-01-20 Дов Фармасьютикал, Инк. (Us) Полиморфы гидрохлорида бицифадина
EP1740593B1 (en) 2004-04-19 2016-04-06 KRKA, tovarna zdravil, d.d., Novo mesto Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
CA2619817A1 (en) 2004-08-18 2006-03-02 Dov Pharmaceutical, Inc. Thermodynamically stable polymorph of an azabicyclohexane
US20070082939A1 (en) 2005-07-26 2007-04-12 Lippa Arnold S Methods and compositions for the treatment of neuropathies and related disorders
ZA200801825B (en) 2005-07-27 2009-12-30 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US20080058535A1 (en) * 2006-07-25 2008-03-06 Zhengming Chen Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
EP2819516B1 (en) * 2011-07-30 2019-12-25 Otsuka America Pharmaceutical, Inc. Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140228421A1 (en) 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
EP3080080A4 (en) 2013-12-09 2017-08-16 Neurovance, Inc. Novel compositions
ES2922158T3 (es) 2015-06-17 2022-09-09 Otsuka America Pharmaceutical Inc Compuestos cristalinos

Also Published As

Publication number Publication date
WO2016205762A1 (en) 2016-12-22
JP2026083082A (ja) 2026-05-19
TW201800392A (zh) 2018-01-01
EP3597189B1 (en) 2022-06-01
AU2021200314B2 (en) 2022-08-04
HUE059348T2 (hu) 2022-11-28
EP3310352A4 (en) 2019-03-13
JP2018517742A (ja) 2018-07-05
JP2021138747A (ja) 2021-09-16
US11299458B2 (en) 2022-04-12
PL3597189T3 (pl) 2022-07-25
EP3310352A1 (en) 2018-04-25
LT3597189T (lt) 2022-07-11
KR20180014830A (ko) 2018-02-09
US9708261B2 (en) 2017-07-18
CN117088802A (zh) 2023-11-21
SG10201911417PA (en) 2020-01-30
US9856217B2 (en) 2018-01-02
AU2016279075B2 (en) 2020-10-22
CN117466800A (zh) 2024-01-30
SI3597189T1 (sl) 2022-08-31
DK3597189T3 (da) 2022-06-27
ES2922158T3 (es) 2022-09-09
TWI751998B (zh) 2022-01-11
JP7583851B2 (ja) 2024-11-14
NZ739044A (en) 2022-08-26
US20210198198A1 (en) 2021-07-01
US20170334850A1 (en) 2017-11-23
AU2021200314A1 (en) 2021-03-18
HRP20220829T1 (hr) 2022-12-23
HK1247125A1 (zh) 2018-09-21
RU2018101244A (ru) 2019-07-22
JP6896651B2 (ja) 2021-06-30
US20260138950A1 (en) 2026-05-21
US20180194726A1 (en) 2018-07-12
CA2989431A1 (en) 2016-12-22
CN107921021A (zh) 2018-04-17
MY194868A (en) 2022-12-21
EP4049997A1 (en) 2022-08-31
US10280141B2 (en) 2019-05-07
MX2017016430A (es) 2018-11-09
MX387591B (es) 2025-03-18
US20160368871A1 (en) 2016-12-22
CA2989431C (en) 2023-08-29
JP2023071978A (ja) 2023-05-23
EP3597189A1 (en) 2020-01-22
US20200039934A1 (en) 2020-02-06
KR102593783B1 (ko) 2023-10-25
MX2020009949A (es) 2020-10-16
PT3597189T (pt) 2022-07-05
AU2016279075C1 (en) 2021-04-01
JP2025022896A (ja) 2025-02-14
CY1125352T1 (el) 2025-05-09
NZ776973A (en) 2022-11-25
PH12017502324A1 (en) 2018-06-25
SA517390552B1 (ar) 2022-04-13
JP7244575B2 (ja) 2023-03-22
RU2018101244A3 (enExample) 2019-12-23
AU2016279075A1 (en) 2018-02-01
US10800740B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
AU2021200314B2 (en) Crystalline compounds
JP2018517742A5 (enExample)
EP1962600A2 (en) Metronidazole cocrystals and imipramine cocrystals
WO2018119291A1 (en) Synthetic methods
HK40077679A (en) Crystalline compounds
HK40020220B (en) Crystalline compounds
HK40020220A (en) Crystalline compounds
RU2789672C2 (ru) Кристаллические соединения
HK40102359A (en) Crystalline compounds
HK40099983A (en) Crystalline compounds
WO2019114394A1 (zh) Eb-1020的晶型及其制备方法和用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230526

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240808

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241007

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250402

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250402

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250513

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250513

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250722

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250722

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20251110

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251110

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251113

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20251113

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251113

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251113

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260429

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260429